UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000005167
Receipt number R000005997
Scientific Title Validation study on the clinical usefulness of the ICG fluoresence method for detecting sentinel lymph node in early breast cancer in comparion with the RI method
Date of disclosure of the study information 2011/03/15
Last modified on 2015/12/09 18:52:57

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Validation study on the clinical usefulness of the ICG fluoresence method for detecting sentinel lymph node in early breast cancer in comparion with the RI method

Acronym

Direct comparison between ICG fluoresence and RI method for SLN biospy

Scientific Title

Validation study on the clinical usefulness of the ICG fluoresence method for detecting sentinel lymph node in early breast cancer in comparion with the RI method

Scientific Title:Acronym

Direct comparison between ICG fluoresence and RI method for SLN biospy

Region

Japan Asia(except Japan)


Condition

Condition

early breast cancer

Classification by specialty

Breast surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To assess the diagnositic performance of SLN biospy using ICG fluorescence technique, prospective multicenter study is performed compared with RI method.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

sensitivity

Key secondary outcomes

1) identification rate of SLN 2)additive effect of ICG fluoresence method on RI method. 3) identificaiton rate of SLN before and after primary systemic therapy. 4) involvement in SLN and non SLN. 5) adverse event of ICG fluoresence method.


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Diagnosis

Type of intervention

Device,equipment

Interventions/Control_1

Sentinel lymph node will be detected by ICG fluoresence method and RI mehod

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

75 years-old >=

Gender

Female

Key inclusion criteria

1)Early breast cancer patients without axillary involvement. 2)Patient who is to undergo SLN biopsy. 3) Written consent to join in this study has been obtained from the patient itself.

Key exclusion criteria

1)Patients who had surgical biopsy or operation on the axilla. 2)Patient who had history of alleragy against ICG reagent or iodine. 3)Pregnant or breast feeding. 4)Patients who are judged inappropriate for the clinical trial by doctors.

Target sample size

840


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Masakazu Toi

Organization

Graduate School of Medicine, Kyoto University

Division name

Breast Surgery

Zip code


Address

54 Shogoin Kawara-cho, Sakyo-ku, Kyoto, Japan

TEL

075-751-3660

Email

toi@kuhp.kyoto-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Tomoharu Sugie

Organization

Graduate School of Medicine Kyoto University

Division name

Breast Surgery

Zip code


Address

54 Shogoin Kawara-cho, Sakyo-ku, Kyoto, Japan

TEL

075-751-3660

Homepage URL


Email

sugie@kuhp.kyoto-u.ac.jp


Sponsor or person

Institute

Kyoto University Hospital

Institute

Department

Personal name



Funding Source

Organization

Hamamatsu Photonics

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

国立がんセンター中央病院(東京都)、昭和大学(東京都)、都立駒込病院(東京都)、北野病院(大阪府)、大阪医療センター(大阪府)


Other administrative information

Date of disclosure of the study information

2011 Year 03 Month 15 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2011 Year 03 Month 23 Day

Date of IRB


Anticipated trial start date

2011 Year 04 Month 01 Day

Last follow-up date


Date of closure to data entry

2013 Year 11 Month 01 Day

Date trial data considered complete

2014 Year 01 Month 15 Day

Date analysis concluded

2014 Year 04 Month 01 Day


Other

Other related information



Management information

Registered date

2011 Year 03 Month 01 Day

Last modified on

2015 Year 12 Month 09 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000005997


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name